SCHEDULE: ADAR1 Capital Management Files Joint Ownership Statement

ADAR1 Capital Management, LLC and Daniel Schneeberger have filed a joint Schedule 13G statement regarding their beneficial ownership of NextCure, Inc. common stock.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger have entered into a joint filing agreement to report their beneficial ownership of NextCure, Inc. common stock.
• The filing indicates that ADAR1 Capital Management, LLC, an investment adviser, and Daniel Schneeberger, its manager, collectively beneficially own 722,419 shares of NextCure, Inc. common stock.
• This ownership represents 15.8% of the class of securities outstanding as of July 31, 2026.
• The shares are held through private investment funds managed by ADAR1 Capital Management and separately managed accounts.
• The filing is made in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine joint filing agreement for Schedule 13G, indicating a change in beneficial ownership reporting rather than new operational or financial performance.

Positives

• Clear disclosure of beneficial ownership by ADAR1 Capital Management and Daniel Schneeberger.
• The filing confirms a significant ownership stake (15.8%) in NextCure, Inc., which could indicate investor confidence or strategic interest.

Negatives

• The filing does not provide any new financial performance data or operational updates for NextCure, Inc.

Risks

• The filing does not explicitly mention any new risks. However, the concentration of ownership by a single entity could pose risks related to concentrated decision-making or potential future selling pressure if the entity decides to divest.

Future Outlook

This filing is a reporting requirement and does not contain forward-looking statements or guidance regarding NextCure, Inc.'s future performance.

Management Comments

• The filing is signed by Daniel Schneeberger, Manager of ADAR1 Capital Management, LLC, and in his individual capacity, certifying that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors and significant shareholders to report their holdings. This particular filing indicates a substantial passive investment in NextCure, Inc. by ADAR1 Capital Management.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant ownership block, which may influence market perception. Other investors will be aware of ADAR1 Capital Management's substantial stake.
• Management of NextCure, Inc.: Management is now aware of the specific reporting entity and individual holding a significant percentage of the company's stock.

Next Steps

• ADAR1 Capital Management, LLC and Daniel Schneeberger will continue to report any changes in their beneficial ownership of NextCure, Inc. common stock as required by SEC regulations.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Joint Filing Agreement, Investment Adviser, NextCure, Inc., ADAR1 Capital Management, Securities Exchange Act